Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Ecolab Inc.    ECL

ECOLAB INC.

(ECL)
  Report
Delayed Quote. Delayed Nyse - 01/22 04:10:00 pm
212.39 USD   -0.76%
01/15ECOLAB : Gabelli Upgrades Ecolab to Buy from Hold
MT
01/12BLUESCOPE STEEL : Names CEO of NS Bluescope
MT
01/11ECOLAB : Schedules Webcast and Conference Call on February 16
BU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Ecolab : Receives First EPA Approval for Biofilm Disinfection in Drains

11/19/2020 | 08:41am EST

Ecolab Inc., the global leader in water, hygiene and infection prevention solutions and services, is the first to receive EPA product approval for disinfection of biofilmsi in wastewater drains for its Virasept™ product – an important part of a comprehensive environmental hygiene program designed to help effectively combat bacterial growth in hospitals.

Virasept (EPA Reg. No. 1677-226) is a patented, peracid mixture, ready-to-use cleaner, deodorizer and hospital disinfectant.

“Effective drain biofilm disinfection reduces the risk of environmental transmission of pathogens found in biofilms,” explains Linda Homan, RN, BSN, CIC, and senior manager of Clinical Affairs for Ecolab Healthcare. “We are excited about this first-to-market foaming application solution and believe it will be unique for some time.”

Because they are wet, drains are a high-risk environment for biofilm growth and a vector for hospital-associated infectionsii, and recently published studies have identified sink drains as potentially important reservoirs for antibiotic-resistant organisms.iii,iv Other published clinical studies have shown that foaming is a more effective way to apply product to drains compared to liquids as it ensures contact time compliance.v,vi,vii

Bringing decades of expertise in infection prevention, the Ecolab team worked together with the EPA to refine the test methods required to show foaming efficacy against these pathogens in drain biofilms.

In addition to this foaming application for drain biofilms, Virasept has broad claims on more than 30 organisms of concern including C. diff, TB, and norovirus.viii It is included on the Environmental Protection Agency’s (EPA) List N: Disinfectants for Use Against SARS-CoV-2.ix As part of this submission, Virasept also received EPA approval for claims against C. auris, Legionella pneumophila, and Listeria monocytogenes, further enhancing its applications.

For more information about Virasept and Ecolab’s line of Healthcare cleaners and disinfection programs, products, equipment and services, please visit:

www.ecolab.com/solutions/cleaners-and-disinfectants-for-hospitals

About Ecolab
A trusted partner at nearly three million commercial customer locations, Ecolab (NYSE:ECL) is the global leader in water, hygiene and infection prevention solutions and services. With annual sales of $13 billion and more than 45,000 associates, Ecolab delivers comprehensive solutions, data-driven insights and personalized service to advance food safety, maintain clean and safe environments, optimize water and energy use, and improve operational efficiencies and sustainability for customers in the food, healthcare, hospitality and industrial markets in more than 170 countries around the world. www.ecolab.com

Follow us on Twitter @ecolab, Facebook at facebook.com/ecolab, LinkedIn at Ecolab or Instagram at Ecolab Inc.

(ECL-P)

i Efficacy studies for disinfection of Staphylococcus aureus and Pseudomonas aeruginosa biofilms were submitted to the EPA to achieve this claim
ii Carling PC. Wastewater drains: epidemiology and interventions in 23 carbapenem-resistant organism outbreaks. Infect Control Hosp Epidemiol. 2018 Aug;39(8):972-979. doi: 10.1017/ice.2018.138. Epub 2018 Jun 28. Review. PubMed PMID: 29950189.
iii BW, Graham MB, Lindmair-Snell J, et al. The relevance of sink proximity to toilets on the detection of Klebsiella pneumoniae carbapenemase

inside sink drains. Am J Infect Control 2019;47:98–100.
iv Kizny Gordon AE, Mathers AJ, Cheong EYL, et al. The hospital water environment as a reservoir for carbapenem-resistant organisms causing hospital-acquired infections—a systematic review of the literature. Clin Infect Dis 2017;64:1435–1444.
v Buchan BW, Arvan JA, Graham MB, Tarima S, Faron ML, Nanchal R, Munoz-Price LS. Effectiveness of a hydrogen peroxide foam against bleach for the disinfection of sink drains. Infect Control Hosp Epidemiol. 2019 Jun;40(6):724-726. doi:10.1017/ice.2019.72. Epub 2019 Apr 17. PubMed PMID: 30992089.
vi Buchan, Blake & Arvan, Jennifer & Graham, Mary & Tarima, Sergey & Faron, Matthew & Nanchal, Rahul & Munoz-Price, L. Silvia. (2019). Effectiveness of a hydrogen peroxide foam against bleach for the disinfection of sink drains. Infection Control & Hospital Epidemiology. 40. 1-3. 10.1017/ice.2019.72.
vii Jones, L., Mana, T., Cadnum, J., Jencson, A., Silva, S., Wilson, B., & Donskey, C. (n.d.). Effectiveness of foam disinfectants in reducing sink-drain gram-negative bacterial colonization. Infection Control & Hospital Epidemiology, 1-6. doi:10.1017/ice.2019.32
viii Claims valid when used in accordance with directions for use on hard, non-porous surfaces
ix Virasept meets criteria for claims against emerging viral pathogens and therefore can be used against COVID-19 when used in accordance with the directions for use against the listed supporting virus on hard, non-porous surfaces.


© Business Wire 2020
All news about ECOLAB INC.
01/15ECOLAB : Gabelli Upgrades Ecolab to Buy from Hold
MT
01/12BLUESCOPE STEEL : Names CEO of NS Bluescope
MT
01/11ECOLAB : Schedules Webcast and Conference Call on February 16
BU
01/06ECOLAB : UBS Adjusts Ecolab's Price Target to $215 From $210, Maintains Neutral ..
MT
01/05ECOLAB INC. : Change in Directors or Principal Officers, Financial Statements an..
AQ
2020ECOLAB : Wins FDA Emergency Use Authorization for N95 Respirator Decontamination..
MT
2020ECOLAB : FDA Authorizes Ecolab's Bioquell Technology System for N95 Respirator D..
BU
2020INSIDER TRENDS : Ecolab Insider Converts Option/Derivative Security Sells Portio..
MT
2020INSIDER TRENDS : 90-Days of Insider Buying at Ecolab Reduced with Share Disposit..
MT
2020ECOLAB : Goldman Sachs Adjusts Price Target for Ecolab to $206 From $181, Mainta..
MT
More news
Financials (USD)
Sales 2020 12 015 M - -
Net income 2020 1 031 M - -
Net Debt 2020 5 658 M - -
P/E ratio 2020 61,3x
Yield 2020 0,92%
Capitalization 60 626 M 60 626 M -
EV / Sales 2020 5,52x
EV / Sales 2021 5,14x
Nbr of Employees 50 200
Free-Float 79,6%
Chart ECOLAB INC.
Duration : Period :
Ecolab Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ECOLAB INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 21
Average target price 212,59 $
Last Close Price 212,39 $
Spread / Highest target 22,4%
Spread / Average Target 0,09%
Spread / Lowest Target -15,3%
EPS Revisions
Managers and Directors
NameTitle
Christophe Beck President, Chief Executive Officer & Director
Douglas M. Baker Chairman
Daniel J. Schmechel Chief Financial Officer & Treasurer
Larry L. Berger Chief Technical Officer & Executive VP
Anil Arcalgud Chief Information Officer & Executive VP
Sector and Competitors
1st jan.Capitalization (M$)
ECOLAB INC.-1.83%60 626
SIKA AG2.40%39 633
GIVAUDAN SA-3.35%37 573
EMS-CHEMIE HOLDING AG-1.76%22 135
SYMRISE AG-6.69%16 675
UMICORE21.05%13 926